12 Cheapest Stocks with Biggest Upside Potential

Page 7 of 11

5. GSK plc (NYSE:GSK)

Upside Potential: 39.62%

Forward P/E Ratio as of January 15: 7.59

Stock Price as of January 15: $32.08

Number of Hedge Fund Investors: 38

GSK plc (NYSE:GSK), formerly known as GlaxoSmithKline, is a British global pharmaceutical and healthcare company. The company develops and markets a wide range of medicines, vaccines, and consumer health products. GSK plc (NYSE:GSK) is a leader in immunology, respiratory treatments, and vaccines for diseases such as influenza and shingles.

GSK plc (NYSE:GSK) is focusing on building on its existing portfolio of long-acting HIV treatments and prevention. The company is developing new regimens for four and six-monthly dosing. A pivotal trial for a four-month long-acting injectable for prevention is slated for 2026, with plans to file and launch in the same year. For treatment, a four-monthly regimen combining long-acting rilpivirine and cabotegravir is in development, with pivotal trials starting in the second half of 2025 and expected to launch in 2027.

GSK plc (NYSE:GSK) is advancing several promising assets in oncology and respiratory, including B7-H3 and B7-H4 antibody-drug conjugates for difficult-to-treat cancers and Camlipixant for refractory chronic cough. The company is also investing in new antibiotics and vaccines. Notable products include Gepotidacin, the first completely new antibiotic for uncomplicated urinary tract infections in over 20 years, and the 5-in-1 MenABCWY vaccine for meningococcal diseases.

Page 7 of 11